Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897)

A trial of the Eastern Cooperative Oncology Group

Stuart Hinton, Paul Catalano, Lawrence Einhorn, Patrick Loehrer, Timothy Kuzel, David Vaughn, George Wilding

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Purpose: Despite great success in the treatment of disseminated germ cell tumors, 20% of patients are incurable and become candidates for investigational therapy. Paclitaxel and gemcitabine have shown activity as single agents in refractory germ cell tumors and can be combined with manageable toxicity. Patients and Methods: Patients with germ cell tumors believed to be incurable with chemotherapy or surgery were treated with paclitaxel 110 mg/m2 and gemcitabine 1,000 mg/m2 intravenously on days 1, 8, and 15 of a 4-week cycle for a maximum of six cycles. Patients were evaluated for response and toxicity. Results: Twenty-eight of 30 enrolled patients were assessable. Toxicity was primarily hematologic but was manageable with only a single case of neutropenic fever. Six (21.4%) of 28 patients responded, including three complete responses. Two of the complete responders were continuously disease-free at 15+ and 25+ months. Conclusion: Paclitaxel plus gemcitabine is an active regimen in refractory germ cell tumors, with an acceptable toxicity profile. This regimen has the possibility for long-term disease-free survival in this refractory patient population.

Original languageEnglish
Pages (from-to)1859-1863
Number of pages5
JournalJournal of Clinical Oncology
Volume20
Issue number7
DOIs
StatePublished - Apr 1 2002
Externally publishedYes

Fingerprint

gemcitabine
Germ Cell and Embryonal Neoplasms
Paclitaxel
Investigational Therapies
Disease-Free Survival
Fever

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897) : A trial of the Eastern Cooperative Oncology Group. / Hinton, Stuart; Catalano, Paul; Einhorn, Lawrence; Loehrer, Patrick; Kuzel, Timothy; Vaughn, David; Wilding, George.

In: Journal of Clinical Oncology, Vol. 20, No. 7, 01.04.2002, p. 1859-1863.

Research output: Contribution to journalArticle

@article{a440dd8e0cbe4ecb93cc8c618913ca75,
title = "Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): A trial of the Eastern Cooperative Oncology Group",
abstract = "Purpose: Despite great success in the treatment of disseminated germ cell tumors, 20{\%} of patients are incurable and become candidates for investigational therapy. Paclitaxel and gemcitabine have shown activity as single agents in refractory germ cell tumors and can be combined with manageable toxicity. Patients and Methods: Patients with germ cell tumors believed to be incurable with chemotherapy or surgery were treated with paclitaxel 110 mg/m2 and gemcitabine 1,000 mg/m2 intravenously on days 1, 8, and 15 of a 4-week cycle for a maximum of six cycles. Patients were evaluated for response and toxicity. Results: Twenty-eight of 30 enrolled patients were assessable. Toxicity was primarily hematologic but was manageable with only a single case of neutropenic fever. Six (21.4{\%}) of 28 patients responded, including three complete responses. Two of the complete responders were continuously disease-free at 15+ and 25+ months. Conclusion: Paclitaxel plus gemcitabine is an active regimen in refractory germ cell tumors, with an acceptable toxicity profile. This regimen has the possibility for long-term disease-free survival in this refractory patient population.",
author = "Stuart Hinton and Paul Catalano and Lawrence Einhorn and Patrick Loehrer and Timothy Kuzel and David Vaughn and George Wilding",
year = "2002",
month = "4",
day = "1",
doi = "10.1200/JCO.2002.07.158",
language = "English",
volume = "20",
pages = "1859--1863",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897)

T2 - A trial of the Eastern Cooperative Oncology Group

AU - Hinton, Stuart

AU - Catalano, Paul

AU - Einhorn, Lawrence

AU - Loehrer, Patrick

AU - Kuzel, Timothy

AU - Vaughn, David

AU - Wilding, George

PY - 2002/4/1

Y1 - 2002/4/1

N2 - Purpose: Despite great success in the treatment of disseminated germ cell tumors, 20% of patients are incurable and become candidates for investigational therapy. Paclitaxel and gemcitabine have shown activity as single agents in refractory germ cell tumors and can be combined with manageable toxicity. Patients and Methods: Patients with germ cell tumors believed to be incurable with chemotherapy or surgery were treated with paclitaxel 110 mg/m2 and gemcitabine 1,000 mg/m2 intravenously on days 1, 8, and 15 of a 4-week cycle for a maximum of six cycles. Patients were evaluated for response and toxicity. Results: Twenty-eight of 30 enrolled patients were assessable. Toxicity was primarily hematologic but was manageable with only a single case of neutropenic fever. Six (21.4%) of 28 patients responded, including three complete responses. Two of the complete responders were continuously disease-free at 15+ and 25+ months. Conclusion: Paclitaxel plus gemcitabine is an active regimen in refractory germ cell tumors, with an acceptable toxicity profile. This regimen has the possibility for long-term disease-free survival in this refractory patient population.

AB - Purpose: Despite great success in the treatment of disseminated germ cell tumors, 20% of patients are incurable and become candidates for investigational therapy. Paclitaxel and gemcitabine have shown activity as single agents in refractory germ cell tumors and can be combined with manageable toxicity. Patients and Methods: Patients with germ cell tumors believed to be incurable with chemotherapy or surgery were treated with paclitaxel 110 mg/m2 and gemcitabine 1,000 mg/m2 intravenously on days 1, 8, and 15 of a 4-week cycle for a maximum of six cycles. Patients were evaluated for response and toxicity. Results: Twenty-eight of 30 enrolled patients were assessable. Toxicity was primarily hematologic but was manageable with only a single case of neutropenic fever. Six (21.4%) of 28 patients responded, including three complete responses. Two of the complete responders were continuously disease-free at 15+ and 25+ months. Conclusion: Paclitaxel plus gemcitabine is an active regimen in refractory germ cell tumors, with an acceptable toxicity profile. This regimen has the possibility for long-term disease-free survival in this refractory patient population.

UR - http://www.scopus.com/inward/record.url?scp=0036534301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036534301&partnerID=8YFLogxK

U2 - 10.1200/JCO.2002.07.158

DO - 10.1200/JCO.2002.07.158

M3 - Article

VL - 20

SP - 1859

EP - 1863

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -